|
Published by: Datamonitor
Published: Sep. 18, 2002 - 33 Pages
Table of Contents
Overview
Introduction
Increasingly, healthcare systems are focusing on postpartum depression as a significant problem that is not currently being adequately addressed. Despite the fact that it has the potential to become a chronic, recurring disorder, it
is still treated as a transitory illness, which not only raises the cost to society over the long-term but also impacts pharmaceutical revenues.
Scope
Detailed analysis about the epidemiology of postpartum depression in 12 separate markets, including diagnosis and drug-treatment rates In-depth profiles of the current clinical data for postpartum depression Analysis of the unique problems facing manufacturers in this market, particularly the decision to opt for safety data as opposed to efficacy results
Outline of the need to develop specific marketing campaign for postpartum depression as it is treated by numerous secondary-care specialists
An illustration of the value of the current postpartum depression, including an outline about how manufacturers can increase their revenue potential
Report Highlights
Although 15% of all women who give birth will suffer from postpartum depression, only 24% are actually diagnosed. This is a major barrier to treatment and needs to be addressed by both manufacturers and healthcare systems. Antidepressant manufacturers need to illustrate the range of problems caused by postpartum depression, from the impact on the development of the infant to the overall cost
of depression to society, and lobby for enhanced screening programs.
Wyeth’s Effexor and Eli Lilly’s Prozac are the leading drugs in terms of clinical research, highlighting the opportunity that exists for other antidepressant manufacturers. Most other manufacturers have only publicized safety data as concerns asre held by physicians and patients about the potential transfer of antidepressant medication through breast milk. However, efficacy data is needed to ramp up the number of patients treated with antidepressant medication.
Postpartum depression represents a significant commercial opportunity for smaller players in the antidepressant market as opposed to the major players. The size of the market is smaller than a number of anxiety disorder markets, which explains why the major manufacturers have concentrated on this area in recent years. However, the size of the depression market means that niche players have an opportunity to establish themselves and considerably enlarge their revenue performance.
Reasons to Purchase
Understand the key issues which have limited the size of the postpartum depression market
Enhance your ability to drive the growth of this market by targeting the appropriate medical specialists
Discover what steps competing players have taken to break into this market
Evaluate the clear opportunities that exist in this market
DRIVERS AND TRENDS
This Market Brief will help answer strategic planning questions such as:
How may patients in 12 major markets are suffering from postpartum depression in 2002
What is the strategy of the major antidepressant manufacturers to gain access to the postpartum depression market?
What are the major physician barriers to commercial success in this market?
What are the major patient barriers to commercial success in this market?
What are the major healthcare system barriers to commercial success in this market?
EPIDEMIOLOGY
An overview of the epidemiology of postpartum depression in 12 separate markets, including a focus on prevalence, diagnosis and drug-treatment rates and a special analysis of treatment length
CURRENT TREATMENT OPTIONS
In-depth profiles of the current clinical data for postpartum depression, including a focus on why many players have opted for a strategy which outlines safety data as opposed to efficacy data
RECOMMENDED MARKETING STRATEGIES
A comprehensive analysis of the need to develop unique marketing strategies for this section of the depression patient population as they are likely to be diagnosed and treated by non-psychiatric secondary care specialists
BARRIERS TO COMMERCIAL SUCCESS
An overview of the main barriers to commercial success in the postpartum depression market (e.g. patient apathy towards pharmacological therapy and the undervalued attitude towards postpartum depression held by many healthcare systems) and how pharmaceutical manufacturers can overcome this and increase their revenue potential
ACTION POINTS
Action Point 1: Antidepressant manufacturers need to supplement their safety data with efficacy data to ramp up revenues of pharmacological therapies.
Action Point 2: Manufacturers need to target non-psychiatric secondary care specialists (e.g. pediatricians) to improve the diagnosis rate of postpartum depression
Action Point 3: Datamonitor advises a physician-led education campaign for target patients to outline the dangers and potentially chronicity of postpartum depression.
Action Point 4: By outlining the impact of postpartum depression upon the development of infants, pharmaceutical manufacturers are likely to have a greater chance of persuading healthcare systems to increase the level of postpartum depression screening.
DATASETS
Table 1: Prevalence of postpartum depression, 2002
Table 2: Diagnosis and drug-treatment rates of postpartum depression, 2002
Table 3: Current postpartum depression patient base and treatment length, 2002
Table 4: Estimated postpartum depression market, 2002
Table 5: Patient potential of the postpartum depression market
Table 6: Potential revenues from the postpartum depression market
Figure 1: The main barriers to revenues for antidepressant manufacturers competing in the postpartum depression market
Figure 2: Symptoms of postpartum depression
Figure 3: Risk factors of postpartum depression
AbstractIntroduction: Increasingly, healthcare systems focus on postpartum depression as a significant problem that is not currently being adequately addressed. Despite the fact that it has the potential to become a chronic, recurring disorder, it is still treated as a transitory illness, raising the cost to society and impacting pharmaceutical revenues. Scope of the Report: * Detailed epidemiology analysis covering 12 separate markets, including diagnosis and drug-treatment rates * In-depth profiles of current clinical data * Analysis of the unique problems facing manufacturers, particularly the decision to opt for safety data rather than efficacy results * Outline of the need to develop specific marketing campaigns for postpartum depression as it is treated by numerous secondary-care specialists * An illustration of the value of the current market, including an outline of how the revenue potential can be increased. Report Highlights: Although 15% of all women who give birth will suffer from postpartum depression, only 24% are actually diagnosed. This is a major barrier to treatment and needs to be addressed by both manufacturers and healthcare systems. Antidepressant manufacturers need to illustrate the range of problems caused by postpartum depression, and lobby for enhanced screening programs. Wyeth's Effexor and Eli Lilly's Prozac are the leading drugs in terms of clinical research, highlighting the opportunity that exists for other antidepressant manufacturers. Most other manufacturers have only publicized safety data as concerns are held by physicians and patients about the potential transfer of antidepressant medication through breast milk. However, efficacy data is needed to ramp up the number of patients treated with antidepressant medication. Postpartum depression represents a significant commercial opportunity for smaller players in the antidepressant market as opposed to the major players. The size of the market is smaller than a number of anxiety disorder markets, which explains why the major manufacturers have concentrated on this area in recent years. However, the size of the depression market means that niche players have an opportunity to establish themselves and considerably enhance their revenue performance. Key Reasons to Buy this Report: * Understand the key issues which have limited the size of the market * Enhance your ability to drive the growth by targeting the appropriate medical specialists * Discover what steps competing players have taken * Evaluate the clear opportunities that exist
Get Full Details About This Report >>
|
